EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study

Philip Ahle Erichsen, Ida M Heerfordt iD, Rasmus Huan Olsen, Mette Mogensen, Kim Peder Dalhoff, Henrik Horwitz

Dermatology · 06.11.2026

DOI: 10.1159/drm/ackag032 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Dermatology, online erschienen am 06.11.2026. Verfasst von Philip Ahle Erichsen und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti-diabetic dipeptidyl peptidase-4 inhibitors (DPP-4i) are associated with an increased risk of bullous pemphigoid (BP), but Danish population-based data, including product specific estimates, are lacking.

Methods

We conducted a nationwide matched case-control study in Denmark of incident BP cases diagnosed between 2007 and 2024. BP cases were matched 1:100 to population controls using risk set sampling based on age, sex, and index date. DPP-4i exposure was defined as at least one redeemed prescription before the index date (ever use) or during the preceding three months (current use). In a specificity analysis, we compared DPP-4i users and users of other type 2 antidiabetics without DPP-4i use with non-users of type 2 diabetes medications. Odds ratios (ORs) with 95% CIs were estimated using conditional logistic regression.

Results

We identified 2,497 incident BP cases and 249,700 controls (median age 78 years). DPP-4i exposure was more common among BP cases for both ever use (OR: 3.81, 95% CI: 3.31-4.40) and current use (OR: 5.59, 95% CI: 4.70-6.63). For current use, the highest odds ratios were observed for vildagliptin (OR: 10.82, 95% CI: 6.73-17.41) and linagliptin (OR: 9.86, 95% CI: 7.33-13.25), whereas the estimate for sitagliptin was lower (OR: 2.46, 95% CI: 1.65-3.66). In the specificity analysis, other antidiabetic therapies did not show a similarly increased risk of BP.

Conclusion

In the Danish population there was a strong association between DPP-4i use and incident BP. This was most pronounced for vildagliptin and linagliptin while the signal was weaker for sitagliptin.

Autor:innen und Institutionen

ORCID-Profile: Ida M Heerfordt

Zitieren

APA

Ahle Erichsen, P., Heerfordt, I. M., Huan Olsen, R., Mogensen, M., Dalhoff, K. P., & Horwitz, H. (2026). Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study. Dermatology. https://doi.org/10.1159/drm/ackag032

Vancouver

Ahle Erichsen P, Heerfordt IM, Huan Olsen R, Mogensen M, Dalhoff KP, Horwitz H. Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study. Dermatology. 2026. doi:10.1159/drm/ackag032

BibTeX
@article{AhleErichsen2026,
  author = {Ahle Erichsen, Philip and Heerfordt, Ida M and Huan Olsen, Rasmus and Mogensen, Mette and Dalhoff, Kim Peder and Horwitz, Henrik},
  title = {Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study},
  journal = {Dermatology},
  year = {2026},
  doi = {10.1159/drm/ackag032}
}
Kostenlos starten →